Evidence map›Paper›PMID 38519492›Full record

ArticleCell death discovery2024

FBXO22 promotes glioblastoma malignant progression by mediating VHL ubiquitination and degradation.

Zhigang Shen, Tao Dong, Hongmei Yong, Chuyin Deng, Changxiu Chen, Xintian Chen, Miaolei Chen, Sufang Chu, Junnian Zheng, Zhongwei Li and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cell death discovery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Von Hippel-Lindau/Hypoxia Inducible Factor Axis in Glioblastoma.International journal of molecular sciences · 2025
    Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Zhigang Shen *Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Tao Dong *Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Hongmei Yong *Department of Oncology, The Affiliated Huai'an Hospital of Xuzhou Medical University and The Second People's Hospital of Huai'an, Huaian, Jiangsu, China.
Chuyin DengCancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Changxiu ChenDepartment of Pediatrics, the Affiliated Huaihai Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Xintian ChenCancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Miaolei ChenCancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Sufang ChuCancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Junnian ZhengCancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China. jnzheng@xzhmu.edu.cn.ORCID http://orcid.org/0000-0003-0208-6410
Zhongwei LiCancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China. lizw074@wnmc.edu.cn.ORCID http://orcid.org/0000-0003-1014-4238
Jin BaiCancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China. bj@xzhmu.edu.cn.ORCID http://orcid.org/0000-0003-1524-7893
Xuzhou Medical College · CNJiangsu University · CNWannan Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma (GBM) is the most common malignant primary brain tumor. Despite comprehensive treatment with traditional surgery, radiotherapy, and chemotherapy, the median survival rate is <14.6% and the 5-year survival rate is only 5%. FBXO22, a substrate receptor of the SCF ubiquitin ligases, has been reported to play a promoting role in melanoma, liver cancer, cervical cancer, and other cancers. However, the function of FBXO22 in GBM has not been reported. In the present study, we demonstrate that FBXO22 is highly expressed in glioma and is positively correlated with worse pathological features and shorter survival of GBM patients. We revealed that FBXO22 promotes GBM cell proliferation, angiogenesis, migration, and tumorigenesis in vitro and in vivo. In terms of mechanism, we reveal that FBXO22 decreases VHL expression by directly mediating VHL ubiquitination degradation, which ultimately increases HIF-1α and VEGFA expression. In addition, our data confirm that there are positive correlations among FBXO22, HIF-1α, and VEGFA expression, and there is a negative correlation between FBXO22 and VHL protein expression in glioma patients. Our study strongly indicates that FBXO22 is a promising diagnostic marker and therapeutic target for glioma patients.

Identifiers

PMID38519492
PMCPMC10959977
OpenAlexW4393116908

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.